| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
MacroGenics Inc (NASDAQ: MGNX)
MGNX Technical Analysis
4
| As on 9th Jun 2023 MGNX STOCK Price closed @ 5.56 and we RECOMMEND Sell for LONG-TERM with Stoploss of 6.89 & Strong Sell for SHORT-TERM with Stoploss of 12.90 we also expect STOCK to react on Following IMPORTANT LEVELS. |
MGNXSTOCK Price
| Open | 5.26 | Change | Price | % |
| High | 5.59 | 1 Day | 0.36 | 6.92 |
| Low | 5.17 | 1 Week | 0.46 | 9.02 |
| Close | 5.56 | 1 Month | -1.08 | -16.27 |
| Volume | 627629 | 1 Year | -11.01 | -66.45 |
| 52 Week High 17.38 | 52 Week Low 2.25 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| MGNX Daily Charts |
MGNX Intraday Charts |
Whats New @ Bazaartrend |
MGNX Free Analysis |
|
|
MGNX Important Levels Intraday
| RESISTANCE | 6.37 |
| RESISTANCE | 6.11 |
| RESISTANCE | 5.95 |
| RESISTANCE | 5.79 |
| SUPPORT | 5.33 |
| SUPPORT | 5.17 |
| SUPPORT | 5.01 |
| SUPPORT | 4.75 |
MGNX Forecast April 2024
| 4th UP Forecast | 17.74 |
| 3rd UP Forecast | 13.83 |
| 2nd UP Forecast | 11.42 |
| 1st UP Forecast | 9 |
| 1st DOWN Forecast | 2.12 |
| 2nd DOWN Forecast | -0.3 |
| 3rd DOWN Forecast | -2.71 |
| 4th DOWN Forecast | -6.62 |
MGNX Weekly Forecast
| 4th UP Forecast | 9.30 |
| 3rd UP Forecast | 8.10 |
| 2nd UP Forecast | 7.36 |
| 1st UP Forecast | 6.62 |
| 1st DOWN Forecast | 4.50 |
| 2nd DOWN Forecast | 3.76 |
| 3rd DOWN Forecast | 3.02 |
| 4th DOWN Forecast | 1.82 |
MGNX Forecast2024
| 4th UP Forecast | 35.49 |
| 3rd UP Forecast | 25.89 |
| 2nd UP Forecast | 19.96 |
| 1st UP Forecast | 14.02 |
| 1st DOWN Forecast | -2.9 |
| 2nd DOWN Forecast | -8.84 |
| 3rd DOWN Forecast | -14.77 |
| 4th DOWN Forecast | -24.37 |
MacroGenics Inc ( NASDAQ USA Symbol : MGNX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
MGNX Business Profile
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland. Address: 9704 Medical Center Drive, Rockville, MD, United States, 20850
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service